Alcidion Group Ltd (ASX: ALC) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Alcidion Group Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $330.14 million
P/E Ratio N/A
Dividend Yield N/A
Shares Outstanding 1.05 billion
Earnings per share -0.002
Dividend per share N/A
Year To Date Return 72.97%
Earnings Yield N/A
Franking N/A
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

Should you invest $1,000 in right now?

Before you consider , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

Alcidion Group Ltd (ASX: ALC)
Latest News

ALC ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
YesNo

About Alcidion Group Ltd

Alcidion Group Ltd (ASX: ALC) is a Melbourne-based company focused on developing and licensing a range of software products for use in the healthcare sector. The company’s own brands include Miya, Patientrack and Smartpage and it also distributes selected products developed by its partner organisations.

Alcidion has offices and operations throughout Australia as well as in New Zealand and the United Kingdom. Its technology platforms are designed to improve the accuracy, efficiency and functionality of the often myriad of disconnected IT systems used in healthcare environments. As at October 2020, the company’s platforms are utilised by more than 65,000 users across over 300 hospitals in Australia, New Zealand and the UK.

According to Alcidion, the company is committed to continually innovating in its quest to support clinicians and improve the management and workflow of healthcare operations. Alcidion first listed on the ASX in mid-2011. The Alcidion share price has not been an overly strong performer and, despite reaching as high as 30 cents in late 2019, has spent much of the time since listing trading around or below 10 cents.

ALC Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
02 Dec 2021 $0.32 $-0.01 -3.13% 2,579,679 $0.32 $0.32 $0.31
01 Dec 2021 $0.32 $-0.02 -5.88% 1,287,378 $0.34 $0.34 $0.32
30 Nov 2021 $0.34 $0.02 6.15% 666,701 $0.34 $0.35 $0.34
29 Nov 2021 $0.33 $-0.03 -8.57% 2,133,160 $0.33 $0.34 $0.33
26 Nov 2021 $0.35 $0.01 2.90% 1,218,665 $0.35 $0.36 $0.34
25 Nov 2021 $0.35 $0.01 2.99% 306,415 $0.34 $0.35 $0.34
24 Nov 2021 $0.34 $0.00 0.00% 356,164 $0.34 $0.34 $0.33
23 Nov 2021 $0.34 $-0.01 -2.94% 1,668,172 $0.34 $0.34 $0.33
22 Nov 2021 $0.34 $-0.01 -2.86% 1,074,794 $0.35 $0.35 $0.34
19 Nov 2021 $0.35 $-0.01 -2.78% 915,164 $0.36 $0.36 $0.35
18 Nov 2021 $0.36 $0.01 2.82% 756,071 $0.36 $0.36 $0.35
17 Nov 2021 $0.36 $0.00 0.00% 244,669 $0.36 $0.36 $0.36
16 Nov 2021 $0.36 $-0.02 -5.41% 1,018,146 $0.37 $0.37 $0.36
15 Nov 2021 $0.37 $0.00 0.00% 1,034,533 $0.37 $0.37 $0.37
12 Nov 2021 $0.37 $0.00 0.00% 844,224 $0.37 $0.37 $0.37
11 Nov 2021 $0.37 $0.00 0.00% 1,712,933 $0.38 $0.38 $0.37
10 Nov 2021 $0.37 $0.00 0.00% 1,585,412 $0.37 $0.37 $0.36
09 Nov 2021 $0.37 $0.00 0.00% 714,962 $0.37 $0.37 $0.36
08 Nov 2021 $0.37 $0.00 0.00% 539,815 $0.37 $0.37 $0.36
05 Nov 2021 $0.37 $0.00 0.00% 845,349 $0.37 $0.38 $0.37
04 Nov 2021 $0.37 $0.00 0.00% 818,951 $0.37 $0.38 $0.37
03 Nov 2021 $0.37 $0.01 2.78% 509,235 $0.38 $0.38 $0.37
02 Nov 2021 $0.36 $-0.01 -2.70% 542,090 $0.38 $0.38 $0.36

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
17 May 2021 Simon Chamberlain Buy 295 $100,300
On-market trade.
17 May 2021 Katrina (Kate) Doyle (Quirke) Sell 11 $3,903,632
On-market trade. As per announcement on 18/05/2021.
11 May 2021 Raymond Blight Issued 93 $30,000
Participation in share purchase plan.
11 May 2021 Rebecca Wilson Issued 22 $7,231
Participation in share purchase plan.
11 May 2021 Rebecca Wilson Issued 15 $4,904
Participation in share purchase plan.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Ms Rebecca Wilson Non-Executive DirectorNon-Executive Chairman Jul 2017
Ms Wilson has more than 20 years experience working within the healthcare, technology and life science sectors providing advice on stakeholder communications, issues management, investor and corporate relations, and business strategy to private and public companies, corporations, governments, and asset managers. She advises boards and executive teams on investor relations and commercial strategies and has experience in transactions, including more than 60 IPOs, M&A transactions, and hundreds of capital raisings. Rebecca is an Executive Director of consulting firm WE Worldwide. She is a member and graduate of the Australian Institute of Company Directors (AICD).
Mr Simon Chamberlain Non-Executive Director Jul 2019
Mr has more than 20 years' experience in executive roles at companies including Experian, Medibank Private, Qantas and MedAdvisor and in his current role, leading strategy and marketing at the high growth residential services business, Detector Inspector. Simon led Qantas' entrance into the online hotels business, establishing a profitable, high growth new division. At Medibank, Simon had responsibility across customer channels, data and customer experience. Gaining a better understanding of the complex challenges facing the wider health system led to Simon's role leading strategy for MedAdvisor, where he supported the global expansion of its health technology business.
Professor Malcolm Pradhan Executive Director Feb 2016
Professor Pradhan has over 25 years of experience in Medical Informatics. Malcolm has been a advocate for interoperability, and a sustainable health care system using smart data-driven IT systems that improve patient safety, reduce clinician workloads and support new models of care.
Ms Victoria Weekes Non-Executive Director Sep 2021
Ms Weekes has experience in the banking and finance sectors. Ms Weekes was the immediate past Acting Chair of the Sydney Local Health District Board and is an experienced Non-Executive Director with current appointments including FINSIA, NSW Treasury Audit and Risk, and St George Community Housing. Ms Weekes will Chair Alcidion's Risk Committee from 01/09/2021.
Ms Katrina (Kate) Elizabeth Doyle (Quirke) Chief Executive OfficerExecutive DirectorManaging Director Jul 2018
Ms Quirke has more than 25 years of experience in the healthcare information technology sector. She has been involved in large systems procurements and implementations of healthcare information technology across Australia, New Zealand and South East Asia. Kate's background involves holding leading management roles at some of the largest healthcare software firms where she has had an impact on strategic product direction across the health sector and believes astute application of information technology will support the transformation of healthcare delivery worldwide.
Mr Daniel Sharp Non-Executive Director Sep 2021
Mr Sharp has more than 30 years' experience in capital markets globally, advising the boards of technology and healthcare-based organizations, and with a network of institutional and private wealth investors globally. He is an immediate past Executive Director of Canaccord Genuity and previously held executive senior corporate banking roles with Shaw and Partners and Lodge Partners.
Ms Melanie Jaye Leydin Company Secretary Mar 2019
-
Matthew Gepp Chief Financial Officer
-
Colin McKinnon Chief Operating Officer
-
Melanie Jaye Leydin Company Secretary
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
Mr Malcolm Pradhan 134,582,403 12.84%
Mr Raymond Blight 95,828,781 9.14%
J P Morgan Nominees Australia Pty Limited 55,835,785 5.33%
Isle of Wight Pty Limited 49,405,192 4.71%
Caledonia Nominees Pty Limited 35,976,377 3.43%
Mrs Katrina Doyle 27,793,199 2.65%
Rewmicman Pty Limited 26,026,606 2.48%
Rangiora-London Pty Limited 25,102,251 2.40%
Sandhurst Trustees Limited <JMFG CONSOL A/C> 24,453,360 2.33%
MNMD Pty Limited 18,668,086 1.78%
Citicorp Nominees Pty Limited 18,102,425 1.73%
HSBC Custody Nominees (Australia) Limited 16,552,966 1.58%
Mr Colin MacKinnon + Mrs Maree MacKinnon 9,676,550 0.92%
National Nominees Limited 9,618,072 0.92%
Sandhurst Trustees Limited <CYAN C3G FUND A/C> 7,819,114 0.75%
Rewmicman Pty Limited (i) 7,533,835 0.72%
BNP Paribas Noms Pty Ltd 6,233,372 0.59%
Emerald Shares Pty Limited 6,118,750 0.58%
Cs Third Nominees Pty Limited 5,680,121 0.54%
Mr Vivek Ramakrishnan + Miss Nisha Srinivasan 5,593,121 0.53%

Profile

since

Note